Drug Profile
MP 301
Alternative Names: MP-301Latest Information Update: 18 Oct 2017
Price :
$50
*
At a glance
- Originator Mitochon Pharmaceuticals
- Class Antihypercalcaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Brain-derived neurotrophic factor expression modulators; Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 18 Oct 2017 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
- 18 Oct 2017 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (PO)
- 18 Oct 2017 Discontinued - Preclinical for Obesity in USA (PO)